Akura Medical Secures $53M Series C to Advance VTE Treatment and Expand Global Presence
Akura Medical, a portfolio company of Shifamed focused on venous thromboembolism (VTE) care, announced a $53 million first close in Series C financing. Led by Qatar Investment Authority (QIA) with participation from existing investors, the funding will accelerate development of the Katana™ Thrombectomy System and NavIQ™ quantification software, complete enrollment in the QUADRA-PE clinical study,…